These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36110856)

  • 1. The number of donor HLA-derived T cell epitopes available for indirect antigen presentation determines the risk for vascular rejection after kidney transplantation.
    Betjes MGH; Peereboom ETM; Otten HG; Spierings E
    Front Immunol; 2022; 13():973968. PubMed ID: 36110856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation.
    Senev A; Van Loon E; Lerut E; Coemans M; Callemeyn J; Daniëls L; Kerkhofs J; Koshy P; Kuypers D; Lamarthée B; Sprangers B; Tinel C; Van Craenenbroeck AH; Van Sandt V; Emonds MP; Naesens M
    Am J Kidney Dis; 2022 Dec; 80(6):718-729.e1. PubMed ID: 35690154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIRCHE-II scores prove useful as a predictive biomarker among kidney transplant recipients with rejection: An analysis of indication and follow-up biopsies.
    Spitznagel T; Matter LS; Kaufmann YL; Nilsson J; von Moos S; Schachtner T
    Front Immunol; 2022; 13():949933. PubMed ID: 36059499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mismatch Predicts T Cell-Mediated Rejection and De Novo Donor-Specific Antibody Formation After Living Donor Liver Transplantation.
    Ono K; Ide K; Tanaka Y; Ohira M; Tahara H; Tanimine N; Yamane H; Ohdan H
    Liver Transpl; 2021 Nov; 27(11):1592-1602. PubMed ID: 34310028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic risk stratification of pediatric heart transplant patients by combining HLAMatchmaker and PIRCHE-II.
    Mangiola M; Ellison MA; Marrari M; Bentlejewski C; Sadowski J; Zern D; Niemann M; Feingold B; Webber SA; Zeevi A;
    J Heart Lung Transplant; 2022 Jul; 41(7):952-960. PubMed ID: 35437211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of T and B Cell Epitopes to Predict the Risk of
    Sakamoto S; Iwasaki K; Tomosugi T; Niemann M; Spierings E; Miwa Y; Horimi K; Takeda A; Goto N; Narumi S; Watarai Y; Kobayashi T
    Front Immunol; 2020; 11():2000. PubMed ID: 32973806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High PIRCHE Scores May Allow Risk Stratification of Borderline Rejection in Kidney Transplant Recipients.
    Lezoeva E; Nilsson J; Wüthrich R; Mueller TF; Schachtner T
    Front Immunol; 2022; 13():788818. PubMed ID: 35250973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study.
    Meszaros M; Niemann M; Ursic-Bedoya J; Faure S; Meunier L; Rivière B; Costes-Martineau V; Thevenin C; Pageaux GP
    Transpl Immunol; 2020 Apr; 59():101272. PubMed ID: 32061667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship of distribution frequency of HLA antigen/antibody and PIRCHE score with DSA production and AMR occurrence].
    Zheng J; Kuang PD; Zhang Y; Zhao Q; He XL; Ding XM; Xue WJ
    Zhonghua Yi Xue Za Zhi; 2019 Mar; 99(12):901-906. PubMed ID: 30917438
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between PIRCHE-II scores and de novo allosensitization after reduction of immunosuppression during SARS-CoV-2 infection in kidney transplant recipients.
    Castrezana-Lopez K; Malchow R; Nilsson J; Kokkonen SM; Rho E; von Moos S; Mueller TF; Schachtner T
    Transpl Infect Dis; 2023 Apr; 25(2):e14052. PubMed ID: 36884207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation.
    Peereboom ETM; Matern BM; Tomosugi T; Niemann M; Drylewicz J; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; van Reekum FE; Verhaar MC; Kamburova EG; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed A; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; de Vries APJ; de Fijter JW; Betjes MGH; Roelen DL; Claas FH; Otten HG; Heidt S; van Zuilen AD; Kobayashi T; Geneugelijk K; Spierings E
    Front Immunol; 2021; 12():784040. PubMed ID: 34868064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection.
    Wiebe C; Rush DN; Gibson IW; Pochinco D; Birk PE; Goldberg A; Blydt-Hansen T; Karpinski M; Shaw J; Ho J; Nickerson PW
    Am J Transplant; 2020 Sep; 20(9):2499-2508. PubMed ID: 32185878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation.
    Meneghini M; Crespo E; Niemann M; Torija A; Lloberas N; Pernin V; Fontova P; Melilli E; Favà A; Montero N; Manonelles A; Cruzado JM; Palou E; Martorell J; Grinyó JM; Bestard O
    Front Immunol; 2020; 11():623276. PubMed ID: 33776988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIRCHE-II Is Related to Graft Failure after Kidney Transplantation.
    Geneugelijk K; Niemann M; Drylewicz J; van Zuilen AD; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Hack CE; van Reekum FE; Verhaar MC; Kamburova EG; Bots ML; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Vanderlocht J; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed A; Lardy JNM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; Spierings E
    Front Immunol; 2018; 9():321. PubMed ID: 29556227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can PIRCHE-II Matching Outmatch Traditional HLA Matching?
    Unterrainer C; Döhler B; Niemann M; Lachmann N; Süsal C
    Front Immunol; 2021; 12():631246. PubMed ID: 33717167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching donor and recipient based on predicted indirectly recognizable human leucocyte antigen epitopes.
    Geneugelijk K; Spierings E
    Int J Immunogenet; 2018 Apr; 45(2):41-53. PubMed ID: 29464898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental Data on PIRCHE and T-Cell Reactivity: HLA-DPB1-Derived Peptides Identified by PIRCHE-I Show Binding to HLA-A*02:01 in vitro and T-Cell Activation in vivo.
    Peereboom ETM; Maranus AE; Timmerman LM; Geneugelijk K; Spierings E
    Transfus Med Hemother; 2024 Jun; 51(3):131-139. PubMed ID: 38867810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation.
    Otten HG; Calis JJ; Keşmir C; van Zuilen AD; Spierings E
    Hum Immunol; 2013 Mar; 74(3):290-6. PubMed ID: 23232063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity.
    Wiebe C; Kosmoliaptsis V; Pochinco D; Gibson IW; Ho J; Birk PE; Goldberg A; Karpinski M; Shaw J; Rush DN; Nickerson PW
    Am J Transplant; 2019 Jun; 19(6):1708-1719. PubMed ID: 30414349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA.
    Jucaud V
    J Immunol Res; 2017; 2017():2748614. PubMed ID: 28331856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.